Alkermes (ALKS) Revenue Growth (3y) (2013 - 2026)
Alkermes (ALKS) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 2.22% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 4.22% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -0.31% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 9.51% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -1.40% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 28.43% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 8.98% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -7.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.04% |
| Mar 31, 2026 | 10.96% |
| Dec 31, 2025 | 8.07% |
| Sep 30, 2025 | 397.57% |
| Jun 30, 2025 | 396.08% |
| Mar 31, 2025 | 3.24% |
| Dec 31, 2024 | 9.84% |
| Sep 30, 2024 | 8.73% |
| Jun 30, 2024 | 9.53% |
| Mar 31, 2024 | 11.70% |
| Dec 31, 2023 | 10.47% |
| Sep 30, 2023 | 12.86% |
| Jun 30, 2023 | 35.62% |
| Mar 31, 2023 | 5.31% |
| Dec 31, 2022 | 293.51% |
| Sep 30, 2022 | -76.77% |
| Jun 30, 2022 | -77.47% |
| Mar 31, 2022 | 7.68% |
| Dec 31, 2021 | 88.69% |
| Sep 30, 2021 | 5.75% |